Low Back Pain - Pipeline Review, H2 2016


#862985

88pages

Global Markets Direct

$ 2000

In Stock

Low Back Pain - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Low Back Pain Pipeline Review, H2 2016, provides an overview of the Low Back Pain (Central Nervous System) pipeline landscape.

Low back pain can happen anywhere below the ribs and above the legs. Causes of low back pain include overuse, strain, or injury, aging, arthritis, illness and cancer involving the spine. Symptoms include tingling or burning sensation, a dull achy feeling, or sharp pain and weakness in legs or feet. Treatment includes pain medications such NSAIDs (non-steroidal anti-inflammatory drugs) or opioids and muscle relaxants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Low Back Pain Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Low Back Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Low Back Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Low Back Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 7, 3, 3 and 2 respectively for Low Back Pain.

Low Back Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Low Back Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Low Back Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Low Back Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Low Back Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Low Back Pain (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Low Back Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Low Back Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Low Back Pain Overview 8
Therapeutics Development 9
Pipeline Products for Low Back Pain - Overview 9
Low Back Pain - Therapeutics under Development by Companies 10
Low Back Pain - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Low Back Pain - Products under Development by Companies 15
Low Back Pain - Companies Involved in Therapeutics Development 16
Adynxx, Inc. 16
Aestus Therapeutics, Inc. 17
Array BioPharma Inc. 18
Axsome Therapeutics Inc 19
Boehringer Ingelheim GmbH 20
Egalet Corporation 21
Frontier Biotechnologies Co., Ltd 22
Gador S.A. 23
Grunenthal GmbH 24
Hisamitsu Pharmaceutical Co., Inc. 25
Immune Pharmaceuticals Inc. 26
KPI Therapeutics, Inc. 27
MD Biosciences GmbH 28
Mesoblast Limited 29
Nektar Therapeutics 30
Orion Oyj 31
Pacira Pharmaceuticals, Inc. 32
Pfizer Inc. 33
Stayble Therapeutics AB 34
Sun Pharma Advanced Research Company Ltd. 35
Low Back Pain - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
(loxoprofen + methocarbamol) - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
AB-001 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
ARRY-954 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
ATX-09002 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
AYX-2 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
bupivacaine - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
cebranopadol - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
dexmedetomidine hydrochloride - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Drug for Chronic Low Back Pain - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
HP-3150 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
IG-8801 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
lidocaine hydrochloride - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
MD-22 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
MPC-06ID - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
NKTR-181 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
oxycodone hydrochloride ER - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
SPARC-1401 - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
tanezumab - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
U-2902 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
zoledronic acid - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Low Back Pain - Dormant Projects 80
Low Back Pain - Discontinued Products 82
Low Back Pain - Product Development Milestones 83
Featured News & Press Releases 83
Aug 01, 2016: MesoblastS Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science 83
Jun 22, 2016: Frontier Biotech Reports Primary Endpoint Met in Phase 2 Trial of AB001 In Chronic Low Back Pain 84
Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms 84
Feb 25, 2015: Nektar Announces Start of Phase 3 SUMMIT-07 Study of NKTR-181 in Patients with Chronic Low Back Pain 85
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 87
Disclaimer 88

List of Tables
Number of Products under Development for Low Back Pain, H2 2016 9
Number of Products under Development by Companies, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Low Back Pain - Pipeline by Adynxx, Inc., H2 2016 16
Low Back Pain - Pipeline by Aestus Therapeutics, Inc., H2 2016 17
Low Back Pain - Pipeline by Array BioPharma Inc., H2 2016 18
Low Back Pain - Pipeline by Axsome Therapeutics Inc, H2 2016 19
Low Back Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2016 20
Low Back Pain - Pipeline by Egalet Corporation, H2 2016 21
Low Back Pain - Pipeline by Frontier Biotechnologies Co., Ltd, H2 2016 22
Low Back Pain - Pipeline by Gador S.A., H2 2016 23
Low Back Pain - Pipeline by Grunenthal GmbH, H2 2016 24
Low Back Pain - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2016 25
Low Back Pain - Pipeline by Immune Pharmaceuticals Inc., H2 2016 26
Low Back Pain - Pipeline by KPI Therapeutics, Inc., H2 2016 27
Low Back Pain - Pipeline by MD Biosciences GmbH, H2 2016 28
Low Back Pain - Pipeline by Mesoblast Limited, H2 2016 29
Low Back Pain - Pipeline by Nektar Therapeutics, H2 2016 30
Low Back Pain - Pipeline by Orion Oyj, H2 2016 31
Low Back Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016 32
Low Back Pain - Pipeline by Pfizer Inc., H2 2016 33
Low Back Pain - Pipeline by Stayble Therapeutics AB, H2 2016 34
Low Back Pain - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 35
Assessment by Monotherapy Products, H2 2016 36
Assessment by Combination Products, H2 2016 37
Number of Products by Stage and Target, H2 2016 39
Number of Products by Stage and Mechanism of Action, H2 2016 41
Number of Products by Stage and Route of Administration, H2 2016 43
Number of Products by Stage and Molecule Type, H2 2016 45
Low Back Pain - Dormant Projects, H2 2016 80
Low Back Pain - Dormant Projects (Contd..1), H2 2016 81
Low Back Pain - Discontinued Products, H2 2016 82

List of Figures
Number of Products under Development for Low Back Pain, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Assessment by Monotherapy Products, H2 2016 36
Number of Products by Targets, H2 2016 38
Number of Products by Stage and Targets, H2 2016 38
Number of Products by Top 10 Mechanism of Actions, H2 2016 40
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 40
Number of Products by Top 10 Routes of Administration, H2 2016 42
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 42
Number of Products by Molecule Types, H2 2016 44
Number of Products by Stage and Molecule Types, H2 2016 44